← Home / GILEAD SCIENCES, INC. (GILD)
Stock Analysis
GILEAD SCIENCES, INC. (GILD)
GILD
GILD · Healthcare • Biotech
130.21 -0.82%
Track GILD in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when GILD price is:
52W Range Position
44%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-07-31 23:56 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 131.02. Holding above 129.74 keeps the current thesis intact.
⚖️
✓
Fundamentals
Moderate / Strong
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
129.74
↗
Break Above
Confirmation improves above resistance.
131.02
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 129.74
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
20
$
Debt Financing
HIGH
GILD debt financing update
Supplemental Indenture On May 20, 2026, Gilead Sciences, Inc.
8-K Filing • SEC EDGAR
MAY
7
●
Financial Results
HIGH
GILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
(Nasdaq: GILD) announced today its results of operations for the first quarter 2026.
8-K Filing • SEC EDGAR
APR
28
◆
M&A
HIGH
GILD merger or acquisition update
As previously disclosed, on February 22, 2026, Gilead entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, the Company and Ravens Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“ Purchaser ”).
8-K Filing • SEC EDGAR
What's Driving GILD?
📈 Technical recovery is improving
Momentum is Neutral. Watch 131.02 for confirmation and 129.74 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 128.98 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 0
Trigger
139.05
Invalidation
139.05
RSI(14)
48.5
◎
How to read this setup
The nearest decision zone is framed by support around 128.98 and resistance near 131.02. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
GILD — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Support
Cash-flow supported
Earnings multiple and free-cash-flow yield look supportive.
Market Cap
$161.7B
Company size
EV
$174.0B
Debt-adjusted value
P/E
17.5
Low multiple
P/S
5.4
Balanced
P/B
6.9
Balanced
EV/Sales
5.9
Balanced
EV/EBIT
16.8
Low multiple
P/FCF
15.8
Low multiple
FCF Yield
6.33%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
High-quality business, softer growth
Financial conditions require selective monitoring.
↗
Revenue Growth
Moderate
●
Profitability
Strong
≈
Cash Flow
Healthy
⚖
Balance Sheet
Strong
💵 Revenue
6.96B
≈ Moderate
📈 Net Income
2.02B
↗ Strong
🧮 EPS (Basic)
0.81
↗ Strong
GILEAD SCIENCES, INC.
Healthcare • Biotech
Related Opportunities